.

Deeper Knowledge, Faster

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Dow
Merck
Argus Health
US Army
Covington
Johnson and Johnson
Accenture
Queensland Health
Chinese Patent Office
Mallinckrodt

Generated: December 17, 2017

DrugPatentWatch Database Preview

Details for Patent: 9,144,549

« Back to Dashboard

Which drugs does patent 9,144,549 protect, and when does it expire?


Patent 9,144,549 protects CONCERTA and is included in one NDA. There have been two Paragraph IV challenges on Concerta.

This patent has sixty-eight patent family members in seventeen countries.

Summary for Patent: 9,144,549

Title:Methods and devices for providing prolonged drug therapy
Abstract: Methods and devices for maintaining a desired therapeutic drug effect over a prolonged therapy period are provided. In particular, oral dosage forms that release drug within the gastrointestinal tract at an ascending release rate over an extended time period are provided. The dosage forms may additionally comprise an immediate-release dose of drug.
Inventor(s): Gupta; Suneel K. (Palo Alto, CA), Guinta; Diane R (Palo Alto, CA), Christopher; Carol A. (Palo Alto, CA), Saks; Samuel R. (Palo Alto, CA), Hamel; Lawrence G. (Palo Alto, CA)
Assignee: ALZA CORPORATION (Palo Alto, CA)
Application Number:13/801,000
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-3,6-13,16-24AND 26-32: METHOD OF TREATING ADHD► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-001Aug 1, 2000ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-004Apr 1, 2002ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-004Apr 1, 2002ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-3,6-13,16-24AND 26-32: METHOD OF TREATING ADHD► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-002Aug 1, 2000ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-002Aug 1, 2000ABRXYesNo► Subscribe► SubscribeFOR CLAIMS 1-3,6-13,16-24AND 26-32: METHOD OF TREATING ADHD► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-003Dec 8, 2000ABRXYesYes► Subscribe► SubscribeFOR CLAIMS 1-3,6-13,16-24AND 26-32: METHOD OF TREATING ADHD► Subscribe
Janssen PharmsCONCERTAmethylphenidate hydrochlorideTABLET, EXTENDED RELEASE;ORAL021121-003Dec 8, 2000ABRXYesYes► Subscribe► SubscribeFOR CLAIMS 1-4,6-14,16-24 AND 26-32: METHOD OF TREATING ADHD IN CHILDREN 6 YEARS OF AGE AND OLDER AND ADOLESCENTS► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Patent: 9,144,549

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,521,067Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
9,000,038Methods and devices for providing prolonged drug therapy► Subscribe
2,015,125,493► Subscribe
8,163,798Methods and devices for providing prolonged drug therapy► Subscribe
9,029,416Methods and devices for providing prolonged drug therapy► Subscribe
8,323,691Methods and apparatus for determining formulation orientation of multi-layered pharmaceutical dosage forms► Subscribe
6,930,129 Methods and devices for providing prolonged drug therapy► Subscribe
6,905,654 Method and apparatus for reducing static charges during polymerization of olefin polymers► Subscribe
8,629,179Methods and devices for providing prolonged drug therapy► Subscribe
6,919,373 Methods and devices for providing prolonged drug therapy► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Patent: 9,144,549

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Portugal1083879► Subscribe
Portugal946151► Subscribe
Portugal932388► Subscribe
New Zealand508567► Subscribe
Norway334409► Subscribe
Norway20130342► Subscribe
Norway333360► Subscribe
Norway20101070► Subscribe
Norway330235► Subscribe
Norway20006007► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Argus Health
Baxter
Moodys
Johnson and Johnson
UBS
Fish and Richardson
US Department of Justice
Farmers Insurance
McKesson
Deloitte

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot